Literature DB >> 24141770

PTEN functions as a melanoma tumor suppressor by promoting host immune response.

Y Dong1, J-Ae Richards2, R Gupta3, P P Aung2, A Emley2, Y Kluger3, S K Dogra4, M Mahalingam2, N Wajapeyee3.   

Abstract

Cancer cells acquire several traits that allow for their survival and progression, including the ability to evade the host immune response. However, the mechanisms by which cancer cells evade host immune responses remain largely elusive. Here we study the phenomena of immune evasion in malignant melanoma cells. We find that the tumor suppressor phosphatase and tensin homolog (PTEN) is an important regulator of the host immune response against melanoma cells. Mechanistically, PTEN represses the expression of immunosuppressive cytokines by blocking the phosphatidylinositide 3-kinase (PI3K) pathway. In melanoma cells lacking PTEN, signal transducer and activator of transcription 3 activates the transcription of immunosuppressive cytokines in a PI3K-dependent manner. Furthermore, conditioned media from PTEN-deficient, patient-derived short-term melanoma cultures and established melanoma cell lines blocked the production of the interleukin-12 (IL-12) in human monocyte-derived dendritic cells. Inhibition of IL-12 production was rescued by restoring PTEN or using neutralizing antibodies against the immunosuppressive cytokines. Furthermore, we report that PTEN, as an alternative mechanism to promote the host immune response against cancer cells, represses the expression of programmed cell death 1 ligand, a known repressor of the host immune response. Finally, to establish the clinical significance of our results, we analyzed malignant melanoma patient samples with or without brisk host responses. These analyses confirmed that PTEN loss is associated with a higher percentage of malignant melanoma samples with non-brisk host responses compared with samples with brisk host responses. Collectively, these results establish that PTEN functions as a melanoma tumor suppressor in part by regulating the host immune response against melanoma cells and highlight the importance of assessing PTEN status before recruiting melanoma patients for immunotherapies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24141770     DOI: 10.1038/onc.2013.409

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  40 in total

Review 1.  The functions of tumor suppressor PTEN in innate and adaptive immunity.

Authors:  Lang Chen; Deyin Guo
Journal:  Cell Mol Immunol       Date:  2017-06-26       Impact factor: 11.530

2.  Genotyping of cutaneous melanoma.

Authors:  Isabella C Glitza; Michael A Davies
Journal:  Chin Clin Oncol       Date:  2014-09

Review 3.  The MYC oncogene is a global regulator of the immune response.

Authors:  Stephanie C Casey; Virginie Baylot; Dean W Felsher
Journal:  Blood       Date:  2018-03-07       Impact factor: 22.113

Review 4.  Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy.

Authors:  Daixi Ren; Yuze Hua; Boyao Yu; Xin Ye; Ziheng He; Chunwei Li; Jie Wang; Yongzhen Mo; Xiaoxu Wei; Yunhua Chen; Yujuan Zhou; Qianjin Liao; Hui Wang; Bo Xiang; Ming Zhou; Xiaoling Li; Guiyuan Li; Yong Li; Zhaoyang Zeng; Wei Xiong
Journal:  Mol Cancer       Date:  2020-01-30       Impact factor: 27.401

5.  PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation.

Authors:  Nemanja Rodić; Robert A Anders; James R Eshleman; Ming-Tseh Lin; Haiying Xu; Jung H Kim; Katie Beierl; Shuming Chen; Brandon S Luber; Hao Wang; Suzanne L Topalian; Drew M Pardoll; Janis M Taube
Journal:  Cancer Immunol Res       Date:  2014-11-04       Impact factor: 11.151

Review 6.  Melanoma central nervous system metastases: current approaches, challenges, and opportunities.

Authors:  Justine V Cohen; Hussain Tawbi; Kim A Margolin; Ravi Amravadi; Marcus Bosenberg; Priscilla K Brastianos; Veronica L Chiang; John de Groot; Isabella C Glitza; Meenhard Herlyn; Sheri L Holmen; Lucia B Jilaveanu; Andrew Lassman; Stergios Moschos; Michael A Postow; Reena Thomas; John A Tsiouris; Patrick Wen; Richard M White; Timothy Turnham; Michael A Davies; Harriet M Kluger
Journal:  Pigment Cell Melanoma Res       Date:  2016-10-22       Impact factor: 4.693

7.  Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations.

Authors:  Amanda D Bucheit; Guo Chen; Alan Siroy; Michael Tetzlaff; Russell Broaddus; Denai Milton; Patricia Fox; Roland Bassett; Patrick Hwu; Jeffrey E Gershenwald; Alexander J Lazar; Michael A Davies
Journal:  Clin Cancer Res       Date:  2014-08-27       Impact factor: 12.531

8.  Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

Authors:  Weiyi Peng; Jie Qing Chen; Chengwen Liu; Shruti Malu; Caitlin Creasy; Michael T Tetzlaff; Chunyu Xu; Jodi A McKenzie; Chunlei Zhang; Xiaoxuan Liang; Leila J Williams; Wanleng Deng; Guo Chen; Rina Mbofung; Alexander J Lazar; Carlos A Torres-Cabala; Zachary A Cooper; Pei-Ling Chen; Trang N Tieu; Stefani Spranger; Xiaoxing Yu; Chantale Bernatchez; Marie-Andree Forget; Cara Haymaker; Rodabe Amaria; Jennifer L McQuade; Isabella C Glitza; Tina Cascone; Haiyan S Li; Lawrence N Kwong; Timothy P Heffernan; Jianhua Hu; Roland L Bassett; Marcus W Bosenberg; Scott E Woodman; Willem W Overwijk; Gregory Lizée; Jason Roszik; Thomas F Gajewski; Jennifer A Wargo; Jeffrey E Gershenwald; Laszlo Radvanyi; Michael A Davies; Patrick Hwu
Journal:  Cancer Discov       Date:  2015-12-08       Impact factor: 39.397

9.  High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.

Authors:  N Shao; Q Cai
Journal:  Clin Transl Oncol       Date:  2015-08-05       Impact factor: 3.405

10.  A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors.

Authors:  Clinton Yam; Xiaowei Xu; Michael A Davies; Phyllis A Gimotty; Jennifer J D Morrissette; Michael T Tetzlaff; Khalida M Wani; Shujing Liu; Wanleng Deng; Meghan Buckley; Jianhua Zhao; Ravi K Amaravadi; Naomi B Haas; Ragini R Kudchadkar; Anna C Pavlick; Jeffrey A Sosman; Hussein Tawbi; Luke Walker; Lynn M Schuchter; Giorgos C Karakousis; Tara C Gangadhar
Journal:  Clin Cancer Res       Date:  2017-10-19       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.